Clinical Trials Sponsored by Merz Pharmaceuticals

Total 19893 results

Merz Therapeutics GmbH

Recruiting

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury (PaiNT)

Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury

Bulgaria, Germany, Poland, France, Hungary, Spain
Merz Therapeutics GmbH

Completed

Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss

Diffuse Hair Loss in Females

Germany
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines (ULTRA I)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

United States
Merz Pharmaceuticals GmbH

Completed

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy (XARA)

Cerebral Palsy | Spasticity

Poland, Russian Federation, Ukraine, United States, Argentina, Mexico
Merz Pharmaceuticals GmbH

Completed

Botulinum Toxin A to Treat Arm Tremor

Essential Tremor of the Upper Limbs

United States, Canada
Merz Pharmaceuticals GmbH

Completed

Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation (ELISE)

Subjects Desiring Lip Augmentation

Germany
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (SIAXI)

Parkinson's Disease | Traumatic Brain Injury | Chronic Troublesome Sialorrhea | Post-stroke

Germany, Poland
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid

Bilateral Blepharospasm (BEB)

Greece, Malaysia, Sri Lanka
Merz Pharmaceuticals GmbH

Completed

Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy

Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy

Poland, Austria, Czechia, Estonia, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Turkey, Ukraine
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

Spasticity of the Upper and Lower Limb Due to Cerebral Causes

Germany, United States, Canada, France, Italy, Norway, Portugal, Spain
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Merz Pharmaceuticals GmbH

Completed

Effectiveness and Safety Study of Overnight Intensive Patch in Scars

Post Dermatological Surgery Scars

Germany
Merz Pharmaceuticals GmbH

Withdrawn

Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders (Snoring)

Sleep-Disordered Breathing
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles

Lateral Periorbital Wrinkles

France, United Kingdom, Germany, Italy
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
Merz Pharmaceuticals GmbH

Completed

Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

Healthy

United States
Merz Pharmaceuticals GmbH

Completed

Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects

Healthy Subjects

Germany
Merz Pharmaceuticals GmbH

Completed

A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects

Metabolism of Neramexane

Belgium
Merz Pharmaceuticals GmbH

Completed

Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane

Healthy Subjects

Germany
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Nystagmus, Acquired | Nystagmus, Congenital Idiopathic

United Kingdom
Merz Therapeutics GmbH

Completed

Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool (I-REFER)

Post-stroke Spasticity

Austria
Merz Pharmaceuticals GmbH

Recruiting

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PATTERN)

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

United States, Belgium, Czechia, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, Australia, Hungary, Norway, Slovakia, Ukraine, Russian Federation
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability (SIPEXI)

Stroke | Cerebral Palsy | Intellectual Disability | Traumatic Brain Injury | Chronic Troublesome Sialorrhea

Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine
Merz Pharmaceuticals GmbH

Completed

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy

Lower Limb Spasticity Due to Cerebral Palsy

Poland, Austria, Czechia, Estonia, France, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Glabellar Lines

United States, Germany, Canada
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke (PURE)

Post-stroke Spasticity of the Upper Limb

Poland, United States, Czech Republic, Germany, Hungary, India, Russian Federation
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke (PLUS)

Post-stroke Spasticity of the Lower Limb

Germany, Poland, Spain, United States, Czech Republic, Russian Federation, Canada, France, Italy
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

Cervical Dystonia

United States
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Blepharospasm

United States, Canada
Merz Pharmaceuticals GmbH

Completed

Memantine and Validation of a New Alzheimer's Disease Scale

Alzheimer's Disease

Germany
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Subjective Tinnitus

United States, Austria, Germany, Brazil, Mexico
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Healthy

Germany
Merz Pharmaceuticals GmbH

Terminated

Blepharospasm Short Interval

Blepharospasm

Germany
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Merz Pharmaceuticals GmbH

Terminated

Memantine and Antipsychotics Use (MemAP)

Alzheimer's Disease

Germany
Merz Pharmaceuticals GmbH

Completed

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Merz Pharmaceuticals GmbH

Completed

Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate

Healthy

Germany
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity (NT-Spin)

Upper Limb Spasticity

France, Spain, Switzerland, United Kingdom, Italy, Austria, Germany, Portugal
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Subjective Tinnitus

Belgium, Czech Republic, France, Poland, South Africa, Netherlands
Merz Pharmaceuticals GmbH

Completed

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Essential Tremor of the Upper Limb

United States, Canada, Poland
Merz Pharmaceuticals GmbH

Completed

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

N/A, as no Specific Medical Condition Will be Treated

Germany
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines. (ULTRA II)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Germany
Merz Pharmaceuticals GmbH

Completed

Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face (POMET)

Correction of Facial Wrinkles/Folds | Facial Volume Enhancement

Germany
Merz Pharmaceuticals GmbH

Completed

Contractubex Treatment in Scars After Abdominal Caesarean Section (ConMex)

Scars

Mexico
Merz Pharmaceuticals GmbH

Completed

Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients

Healthy Volunteers and Glaucoma Patients

Germany
Merz Pharmaceuticals GmbH

Completed

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

Memory Disorder | Subjective Cognitive Impairment | Retention Disorder, Cognitive | Memory, Concentration or Attention Problems

United Kingdom, Germany
Merz Pharmaceuticals GmbH

Terminated

Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring

Habitual Snoring

Germany
Merz Pharmaceuticals GmbH

Completed

Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia

Cervical Dystonia

Germany
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Moderate to Severe Glabellar Frown Lines

United States, Canada
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain

Clinical Trials Sponsored by Merz Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations